Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury
Edesa Biotech (Nasdaq: EDSA) reported exploratory post hoc data for paridiprubart in 101 hospitalized patients with acute kidney injury (AKI) and respiratory distress, drawn from prior Phase 2/3 ARDS studies.
Rhea-AI Summary
Edesa Biotech (Nasdaq: EDSA) reported exploratory post hoc data for paridiprubart in 101 hospitalized patients with acute kidney injury (AKI) and respiratory distress, drawn from prior Phase 2/3 ARDS studies.
Paridiprubart plus standard of care was associated with lower adjusted 28‑day mortality and MAKE30 incidence, with a safety profile comparable to placebo. Results are exploratory and require confirmatory studies.
Positive
- Adjusted 28-day mortality 33% with paridiprubart vs 49% with placebo in AKI cohort
- 32% relative reduction in risk of death at 28 days (nominal p<0.005)
- MAKE30 incidence 41% with paridiprubart vs 53% with placebo, 23% relative reduction
- Exploratory kidney outcomes directionally consistent with prior Phase 3 ARDS results
- Safety profile in AKI subgroup comparable to placebo with low adverse event rates
- Abstract selected for oral presentation at 63rd European Renal Association Congress
Negative
- Analyses are post hoc, exploratory and not prespecified in original trial designs
- Nominal p-values not adjusted for multiplicity, increasing risk of false-positive findings
- Efficacy in AKI not established; confirmatory prospective studies still required
- AKI subgroup size limited to 101 patients from combined Phase 2 and Phase 3 populations
Details
News Market Reaction – EDSA
In the Jun 5 session, EDSA declined 22.99%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- AKI cohort size
- 101 patients
- Combined AKI subgroup from Phase 2 and Phase 3 studies
- Mortality reduction
- 32% relative reduction
- 28-day mortality in AKI patients, paridiprubart + SOC vs placebo + SOC
- 28-day mortality rates
- 33% vs 49%
- Adjusted 28-day mortality, paridiprubart + SOC vs placebo + SOC
- MAKE30 incidence
- 41% vs 53%
- Adjusted MAKE30 at Day 30, paridiprubart + SOC vs placebo + SOC
- Treatment population
- 278 patients
- Broader ARDS treatment population referenced for analyses
- Baseline ARDS severity
- ≈90% moderate-to-severe
- Proportion of AKI cohort with moderate-to-severe ARDS at baseline
- IMV/ECMO use
- ≈50% of patients
- AKI cohort requiring invasive mechanical ventilation or ECMO
- Mean age
- 58 years
- AKI cohort baseline demographics
Historical Context
-
Announcement of upcoming paridiprubart AKI data presentation at ERA Congress.
-
Fiscal Q2 2026 results with net loss and multiple clinical program updates.
-
Invitation for oral and poster presentations of Phase 3 paridiprubart data at ATS.
-
Advancement of EB06 vitiligo program toward Phase 2 enrollment mid-2026.
-
Additional positive Phase 3 ARDS results for paridiprubart with reduced mortality.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
acute kidney injury medical
acute respiratory distress syndrome medical
ARDS medical
ECMO medical
Major Adverse Kidney Events at 30 days medical
multivariate logistic regression technical
monoclonal antibody medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Analyses demonstrate consistent positive signals across endpoints in AKI patients
- Findings derived from post hoc analysis of 101 patients also experiencing respiratory distress
- New data and analysis to be presented today at the 63rd European Renal Association Congress
TORONTO, June 05, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company developing host-directed therapeutics for immuno-inflammatory diseases, today reported favorable exploratory data for paridiprubart, its first-in-class anti-TLR4 monoclonal antibody, in patients with acute kidney injury (AKI) and respiratory distress.
The data, which expand upon previously reported Phase 3 clinical results through new exploratory analyses, will be presented today in a scientific oral presentation at the 63rd European Renal Association (ERA) Congress in Glasgow, Scotland. These new analyses are based on exploratory evaluations from the company’s completed clinical studies in hospitalized patients with acute respiratory distress syndrome (ARDS).
Because TLR4-mediated inflammation plays a central role in both lung and kidney injury, Edesa conducted additional analyses to evaluate paridiprubart’s effect in patients with concurrent AKI, a high-mortality complication that currently lacks approved, targeted pharmacological therapies. Patients with AKI and ARDS represent a high-risk population, with substantially elevated mortality relative to patients without renal dysfunction. Among the findings, paridiprubart plus standard of care treatments (SOC) was associated with a
“These exploratory findings in a high-risk subgroup provide an important clinical perspective on how paridiprubart’s mechanism of action may translate beyond the lungs. Acute kidney injury shares many of the same inflammatory pathways seen in severe respiratory illness, and the consistency we’re observing across these larger analyses helps reinforce the biological rationale for further evaluation in AKI patients,” said Par Nijhawan, MD, Chief Executive Officer of Edesa Biotech.
Key Findings*
The AKI findings reported here expand on previously reported exploratory results in 48 AKI patients from the Phase 3 ITT population by incorporating additional patients from the Phase 2 study and the broader 278-patient treatment population, for a combined AKI cohort of 101 patients. The AKI subgroup included all patients with AKI present at baseline, and outcomes were analyzed using the same multivariate methodology prespecified in the Phase 3 statistical analysis plan for ARDS.
Patients in this AKI cohort were severely ill, with approximately
28-Day Mortality
Paridiprubart + SOC reduced adjusted 28-day mortality to
MAKE30 (Major Adverse Kidney Events at 30 days)
Using the same multivariate logistic regression methodology, paridiprubart + SOC reduced the adjusted incidence of MAKE30 at Day 30 to
Safety and Tolerability
Paridiprubart was well tolerated in the AKI subpopulation. Overall rates of adverse events, serious adverse events, and infections were low and showed no significant differences between the paridiprubart and placebo groups. The safety profile was consistent with more than 400 patients treated across clinical studies to date.
These exploratory findings are consistent with the hypothesis that modulation of TLR4-mediated inflammation may influence multi-organ dysfunction in critically ill patients, and are directionally consistent with the previously reported Phase 3 results. Since AKI represents a high-mortality subgroup within ARDS, the company believes the consistency of benefit observed here reinforces the rationale for paridiprubart’s ongoing development in ARDS. In addition, the company believes these data support further evaluation of paridiprubart in prospective studies specifically targeting patients with AKI and may inform the design of future clinical trials in this high-unmet need population.
* Estimated using multivariate logistic regression-derived risk differences (
Presentation
Edesa’s abstract was selected for oral presentation at the ERA Congress. The presentation, titled “Exploratory Analysis of Paridiprubart, an Anti-TLR4 Antibody, in Patients with Acute Kidney Injury and Respiratory Distress,” is scheduled today at approximately 4:30 pm BST. The presentation will be available in the Events section of the Edesa Biotech website.
About Paridiprubart
Paridiprubart is a first-in-class anti-TLR4 (Toll-like Receptor 4) monoclonal antibody designed to modulate the body's immune response. By selectively inhibiting TLR4, paridiprubart is designed to dampen the hyperinflammatory cascade implicated in Acute Respiratory Distress Syndrome (ARDS), AKI, sepsis, pneumonia, and other critical inflammatory conditions. As a host-directed therapeutic, its mechanism is agnostic to the causal agent, offering potential utility across a range of acute conditions and biodefense applications. More than 400 patients have received paridiprubart in clinical studies to date, with a consistent and favorable safety profile.
About Acute Kidney Injury
Acute kidney injury (AKI) is a sudden, often severe decline in kidney function, most commonly occurring in critically ill or hospitalized patients. AKI affects an estimated 13 million people worldwide each year and is associated with high short-term mortality, prolonged hospitalization, and an elevated risk of progression to chronic kidney disease. In AKI, renal ischemia and cellular injury release endogenous TLR4 ligands, triggering a destructive inflammatory cascade that amplifies kidney damage and drives mortality. Despite its prevalence and clinical severity, there are currently no approved pharmacological therapies specifically targeting AKI. Treatment remains largely supportive.
About Edesa Biotech, Inc.
Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Its clinical pipeline is focused on two therapeutic areas: Medical Dermatology and Respiratory. In Medical Dermatology, Edesa is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (
Edesa Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions, including statements related to: the company’s belief that the exploratory findings presented here provide an important clinical perspective on how paridiprubart’s mechanism of action may translate beyond the lungs; the company’s belief that the consistency observed across these analyses helps reinforce the biological rationale for expanded utility and for ongoing development in ARDS; and the company's timing and plans regarding its clinical studies in general. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include: the ability of Edesa to obtain regulatory approval for or successfully commercialize any of its product candidates, the risk that access to sufficient capital to fund Edesa's operations may not be available or may be available on terms that are not commercially favorable to Edesa, the risk that Edesa's product candidates may not be effective against the diseases tested in its clinical trials, the risk that Edesa fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business, Edesa's ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings, and the impacts of public health crises. Many of these factors that will determine actual results are beyond the company's ability to control or predict. For a discussion of further risks and uncertainties related to Edesa's business, please refer to Edesa's public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Edesa assumes no obligation to update such statements.
Contact:
Gary Koppenjan
Edesa Biotech, Inc.
investors@edesabiotech.com
